Masavibart Biosimilar Monoclonal Antibody (SARS-CoV-2 Spike RBD) for Research

Cat No.: GMP-Bios-INN-1279

Anti-SARS-CoV-2 Spike RBD therapeutic antibody (Pre-made Masavibart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Masavibart (development code ZRC-3308A7) is a monoclonal antibody targeting SARS-CoV-2 spike glycoprotein. It is developed by Regeneron Pharmaceuticals and has received regulatory approval.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1279-1mg 1mg 3090
GMP-Bios-INN-1279-10mg 10mg
GMP-Bios-INN-1279-100mg 100mg
GMP-Bios-INN-1279-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Masavibart biosimilar, Whole mAb: Anti-SARS-CoV-2 Spike RBD therapeutic antibody
INN Name Masavibart
Target SARS-CoV-2 Spike RBD
Format Whole mAb
Derivation Human
Species Reactivity Human
CH1+2+3 Isotype G1
VD LC Lambda
Highest_Clin_Trial (Jan '20) Approved
Est. Status Active
100% SI Structure 6xdg:CA/7zjl:ji:jg:lk/8j26:BA/8j1q:BA
99% SI Structure None
95-98% SI Structure None
Year Proposed 2020
Year Recommended 2021
Companies Regeneron Pharmaceuticals
Conditions Approved COVID-19
Conditions Active na
Conditions Discontinued na
Production na
Development Tech na